Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 214

1.

Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?

Boesecke C, Grint D, Soriano V, Lundgren JD, d'Arminio Monforte A, Mitsura VM, Chentsova N, Hadziosmanovic V, Kirk O, Mocroft A, Peters L, Rockstroh JK; EuroSIDA in EuroCoord.

Liver Int. 2015 Apr 15. doi: 10.1111/liv.12848. [Epub ahead of print]

PMID:
25875966
2.

Liver-related death among HIV/hepatitis C virus-co-infected individuals: implications for the era of directly acting antivirals.

Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M, Domingo P, Kirk O, Lundgren JD, Mocroft A; for EuroSIDA in EuroCoord.

AIDS. 2015 Apr 13. [Epub ahead of print]

PMID:
25870984
3.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

4.

Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

Achhra AC, Mocroft A, Ross MJ, Ryom L, Lucas GM, Furrer H, Neuhaus J, Somboonwit C, Kelly M, Gatell JM, Wyatt CM; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group.

HIV Med. 2015 Apr;16 Suppl 1:55-63. doi: 10.1111/hiv.12234.

PMID:
25711324
5.

Thrombocytopenia is associated with an increased risk of cancer during treated HIV disease.

Borges ÁH, Lundgren JD, Ridolfo A, Katlama C, Antunes F, Grzeszczuk A, Blaxhult A, Mitsura VM, Doroana M, Battegay M, Gargalianos P, Mocroft A; EuroSIDA in EuroCOORD.

AIDS. 2014 Nov 13;28(17):2565-71. doi: 10.1097/QAD.0000000000000433.

PMID:
25574959
6.

The effects of HIV-1 subtype and ethnicity on the rate of CD4 cell count decline in patients naive to antiretroviral therapy: a Canadian-European collaborative retrospective cohort study.

Klein MB, Young J, Dunn D, Ledergerber B, Sabin C, Cozzi-Lepri A, Dabis F, Harrigan R, Tan DH, Walmsley S, Gill J, Cooper C, Scherrer AU, Mocroft A, Hogg RS, Smaill F; Canadian−European Clade Collaboration.

CMAJ Open. 2014 Oct 1;2(4):E318-29. doi: 10.9778/cmajo.20140017. eCollection 2014 Oct.

7.

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults.

Marzolini C, Sabin C, Raffi F, Siccardi M, Mussini C, Launay O, Burger D, Roca B, Fehr J, Bonora S, Mocroft A, Obel N, Dauchy FA, Zangerle R, Gogos C, Gianotti N, Ammassari A, Torti C, Ghosn J, Chêne G, Grarup J, Battegay M; Efavirenz, Obesity Project Team on behalf of Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

AIDS. 2015 Jan 14;29(2):193-200. doi: 10.1097/QAD.0000000000000530.

PMID:
25426810
8.

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression.

Llibre JM, Cozzi-Lepri A, La Rosa JA, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura VM, Ormaasen V, Maltez F, Beniowski M, Paredes R; Eurosida in Eurocoord.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19810. doi: 10.7448/IAS.17.4.19810. eCollection 2014.

9.

The prevalence and predictive value of dipstick urine protein in HIV-positive persons in Europe.

Mocroft A, Ryom L, Lapadula G, Reiss P, Blaxhult A, Furrer H, Kutsyna G, Gatell J, Begovac J, Kirk O, Lundgren J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19561. doi: 10.7448/IAS.17.4.19561. eCollection 2014.

10.

Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study.

Hatleberg CI, Ryom L, El-Sadr W, Mocroft A, Reiss P, de Wit S, Dabis F, Pradier C, Monforte Ad, Rickenbach M, Law M, Lundgren J, Sabin C.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19516. doi: 10.7448/IAS.17.4.19516. eCollection 2014.

11.

A clinically useful risk-score for chronic kidney disease in HIV infection.

Mocroft A, Lundgren J, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Heuhaus J, Fux C, Moranne O, Morlat P, Johnson M, Ryom L; Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT study group.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19514. doi: 10.7448/IAS.17.4.19514. eCollection 2014.

12.

Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study.

Smith C, Ryom L, Monforte Ad, Reiss P, Mocroft A, El-Sadr W, Weber R, Law M, Sabin C, Lundgren J.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19512. doi: 10.7448/IAS.17.4.19512. eCollection 2014.

13.

Predictive value of prostate-specific antigen for prostate cancer: a nested case-control study in EuroSIDA.

Shepherd L, Borges AH, Ravn L, Harvey R, Jean-Paul V, Bower M, Grulich A, Silverberg M, De Wit S, Kirk O, Lundgren J, Mocroft A; EuroSIDA in Eurocoord.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19510. doi: 10.7448/IAS.17.4.19510. eCollection 2014.

14.

Major challenges in clinical management of TB/HIV co-infected patients in Eastern Europe compared with Western Europe and Latin America.

Efsen AM, Schultze A, Post F, Panteleev A, Furrer H, Miller R, Skrahin A, Losso MH, Toibaro J, Girardi E, Miro J, Bruyand M, Obel N, Caylá J, Podlekareva D, Lundgren J, Mocroft A, Kirk O.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19505. doi: 10.7448/IAS.17.4.19505. eCollection 2014.

15.

Regional differences in self-reported HIV care and management in the EuroSIDA study.

Laut KG, Mocroft A, Lazarus J, Reiss P, Rockstroh J, Karpov I, Rakhmanova A, Knysz B, Moreno S, Gargalianos P, Lundgren J, Kirk O; Eurosida in Eurocoord.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19504. doi: 10.7448/IAS.17.4.19504. eCollection 2014.

16.

HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective.

Peters L, Mocroft A, Lundgren J, Grint D, Kirk O, Rockstroh J.

BMC Infect Dis. 2014;14 Suppl 6:S13. doi: 10.1186/1471-2334-14-S6-S13. Epub 2014 Sep 19. No abstract available.

17.

Deteriorating renal function and clinical outcomes in HIV-positive persons.

Mocroft A, Ryom L, Begovac J, Monforte AD, Vassilenko A, Gatell J, Florence E, Ormaasen V, Kirk O, Lundgren JD; EuroSIDA in EuroCOORD.

AIDS. 2014 Mar 13;28(5):727-37. doi: 10.1097/QAD.0000000000000134.

PMID:
24983543
18.

A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.

Mocroft A, Reiss P, Rakhmanova A, Banhegyi D, Phillips AN, De Wit S, Ristola M, Lundgren JD, Grarup J, Kirk O; EuroSIDA in EuroCOORD.

Infection. 2014 Aug;42(4):757-62. doi: 10.1007/s15010-014-0630-4. Epub 2014 Jun 6.

19.

High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance.

Peters L, Mocroft A, Soriano V, Rockstroh JK, Kirkby N, Reiss P, Katlama C, Zakharova N, Flisiak R, Lundgren JD; EuroSIDA in EuroCoord.

HIV Med. 2014 Nov;15(10):615-20. doi: 10.1111/hiv.12160. Epub 2014 May 11.

PMID:
24814468
20.

Biomarkers of inflammation, coagulation and microbial translocation in HIV/HCV co-infected patients in the SMART study.

Peters L, Neuhaus J, Duprez D, Neaton JD, Tracy R, Klein MB, Mocroft A, Rockstroh J, Dore G, Lundgren JD; INSIGHT SMART Study Group.

J Clin Virol. 2014 Jul;60(3):295-300. doi: 10.1016/j.jcv.2014.03.017. Epub 2014 Apr 8.

PMID:
24793968
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk